Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1590018

EntreMed, Inc. - Product Pipeline Review - Q1 2011

Description:
EntreMed, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “EntreMed, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- EntreMed, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of EntreMed, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of EntreMed, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the EntreMed, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate EntreMed, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of EntreMed, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the EntreMed, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with EntreMed, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of EntreMed, Inc. and identify potential opportunities in those areas.
 
Contents:


List of Tables
List of Figures
EntreMed, Inc. Snapshot
EntreMed, Inc. Overview
Key Information
Key Facts
EntreMed, Inc. – Research and Development Overview
Key Therapeutic Areas
EntreMed, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
EntreMed, Inc. – Pipeline Products Glance
EntreMed, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
EntreMed, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
EntreMed, Inc. – Drug Profiles
ENMD-2076
Product Description
Mechanism of Action
R&D Progress
MKC-1
Product Description
Mechanism of Action
R&D Progress
MKC-1 + Alimta
Product Description
Mechanism of Action
R&D Progress
Panzem NCD
Product Description
Mechanism of Action
R&D Progress
Panzem NCD + Avastin
Product Description
Mechanism of Action
R&D Progress
Panzem NCD + Sutent
Product Description
Mechanism of Action
R&D Progress
Panzem NCD + Temodar
Product Description
Mechanism of Action
R&D Progress
Recombinant Angiostatin Protein + Paclitaxel + Carboplatin
Product Description
Mechanism of Action
R&D Progress
ENMD-1198
Product Description
Mechanism of Action
R&D Progress
ENMD-2076
Product Description
Mechanism of Action
R&D Progress
MKC-1
Product Description
Mechanism of Action
R&D Progress
Panzem Capsules + Taxotere
Product Description
Mechanism of Action
R&D Progress
Panzem NCD
Product Description
Mechanism of Action
R&D Progress
ENMD-2076
Product Description
Mechanism of Action
R&D Progress
EntreMed, Inc. – Pipeline Analysis
EntreMed, Inc. – Pipeline Products by Therapeutic Class
EntreMed, Inc. - Pipeline Products By Target
EntreMed, Inc. – Pipeline Products by Route of Administration
EntreMed, Inc. – Pipeline Products by Molecule Type
EntreMed, Inc. – Recent Pipeline Updates
EntreMed, Inc. - Dormant Projects
EntreMed, Inc. – Company Statement
EntreMed, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 09, 2010: EntreMed To Present ENMD-2076 Phase I Data In Hematological Studies At ASH Annual Meeting
Nov 09, 2010: EntreMed To Present ENMD-2076 Phase I Data In Hematological Studies At ASH Annual Meeting
Jul 13, 2010: EntreMed’s ENMD-2076 Demonstrates Significant Anti-Cancer Activity In Multiple Myeloma Preclinical Models
Jun 02, 2010: EntreMed's ENMD-2076 Demonstrates Preclinical Antitumor Activity In Colorectal Cancer
May 11, 2010: EntreMed Initiates Second Site In ENMD-2076 Phase II Ovarian Cancer Study
Apr 16, 2010: EntreMed Raises Additional $3 Million To Further Support Clinical Development Of ENMD-2076 In Ovarian Cancer
Apr 13, 2010: EntreMed Begins Phase II Study For ENMD-2076 In Ovarian Cancer
Nov 16, 2009: EntreMed’s ENMD-2076 Active In Solid And Hematological Cancers
Nov 16, 2009: EntreMed’s ENMD-2076 Active In Solid And Hematological Cancers
Nov 03, 2009: EntreMed’s ENMD-2076 To Be Presented At The Upcoming AACR-NCI-EORTC Conference
Financial Deals Landscape
EntreMed, Inc., Deals Volume Summary, 2004 to YTD 2011
EntreMed, Inc., Deals Summary By Region, 2004 to YTD 2011
EntreMed, Inc., Deals Summary, 2004 to YTD 2011
EntreMed, Inc. Detailed Deal Summary
Acquisition
EntreMed Acquires Miikana Therapeutics
Equity Offering
EntreMed Completes Private Placement Of Common Stock For $2.5 Million
EntreMed Completes Private Placement Of $2.5 Million
EntreMed Completes Private Placement Of $17.16 Million
EntreMed Completes Private Placement Of $30 Million
EntreMed Completes Private Placement Of $10.5 Million
EntreMed Completes Private Placement Of $14 Million
EntreMed Enters Into Agreement With UTEK
EntreMed Enters Into Agreement With National Cancer Institute
EntreMed Enters Into Research Collaboration With Affymax
EntreMed Enters Into An Agreement With Children's Medical Center And Alchemgen Therapeutics
Licensing Agreements
EntreMed Enters Into Licensing Agreement With Elan
EntreMed Enters Into Licensing Agreement With Celgene
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
EntreMed, Inc. – Pipeline by Therapy Area and Indication, 2011
EntreMed, Inc. – Pipeline by Stage of Development, 2011
EntreMed, Inc. – Monotherapy Products in Pipeline, 2011
EntreMed, Inc. – Combination Treatment Modalities in Pipeline, 2011
EntreMed, Inc. - Phase II, 2011
EntreMed, Inc. - Phase I, 2011
EntreMed, Inc. - Pipeline By Therapeutic Class, 2011
EntreMed, Inc. - Pipeline By Target, 2011
EntreMed, Inc. – Pipeline By Route of Administration, 2011
EntreMed, Inc. – Pipeline By Molecule Type, 2011
EntreMed, Inc. – Recent Pipeline Updates, 2011
EntreMed, Inc. - Dormant Developmental Projects, 2010
EntreMed, Inc., Subsidiaries
EntreMed, Inc., Deals Summary, 2004 to YTD 2011
EntreMed, Inc., Deals Summary by Region, 2004 to YTD 2011
EntreMed, Inc., Deals Summary, 2004 to YTD 2011

List of Figures
EntreMed, Inc. – Pipeline by Therapy Area and Indication, 2011
EntreMed, Inc. – Pipeline by Stage of Development, 2011
EntreMed, Inc. – Monotherapy Products in Pipeline, 2011
EntreMed, Inc. – Combination Treatment Modalities in Pipeline, 2011
EntreMed, Inc. – Pipeline By Therapeutic Class, 2011
EntreMed, Inc. - Pipeline By Target, 2011
EntreMed, Inc. – Pipeline By Route of Administration, 2011
EntreMed, Inc. – Pipeline By Molecule Type, 2011
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1590018

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Nov 27, 2014
1:18:19 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

EntreMed, Inc. - Product Pipeline Review - Q1 2011

Web Address

http://www.researchandmarkets.com/reports/1590018

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Nov 27, 2014
1:18:19 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)